TRX‐214‐1002 exhibited the significant ability to degrade GSPT1 and enhanced antileukemic activity, particularly in TP53‐mutated and VEN‐resistant AML cell lines, along with significant antitumor activity superior to ORM‐6151.[156]. This evidence concerns the gene GSPT1 and acute myeloid leukemia.